Posted by Michael Wonder on 06 Sep 2018
New agreement makes more medicines available to treat range of health conditions
6 September 2018 - Up to 50,000 New Zealanders per year will benefit from a new multiproduct agreement PHARMAC has reached with Novartis, which makes more funded medicines available for a wide range of health conditions.
“People living with conditions such as chronic heart failure, severe psoriasis, type 2 diabetes, severe asthma and the bone marrow disorder myelofibrosis will be among those who will benefit from this agreement,” says Lisa Williams, PHARMAC Director of Operations.
The agreement includes funding of five new treatments, as well as widened access to three currently funded treatments.
